0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.237.95.6. Please contact the publisher to request reinstatement.
msJAMA |

The Role of Genomics in Public Health and Disease Prevention FREE

Karen K. Steinberg, PhD; Marta Gwinn, MD; Muin J. Khoury, MD, PhD
[+] Author Affiliations

Not Available


Not Available


JAMA. 2001;286(13):1635. doi:10.1001/jama.286.13.1635-JMS1003-3-1.
Text Size: A A A
Published online

Francis Collins and colleagues articulated a vision for using genomics in disease prevention in a "hypothetical case in 2010."1 In this case, a 23-year-old man named John elects to undergo DNA testing for genes related to several diseases. The results suggest that while John is at lower than average risk for prostate cancer and Alzheimer disease, he is at increased risk for lung and colon cancer, as well as for coronary artery disease. Fortunately, preventive interventions are available to help John reduce his risk of developing each of these diseases. Making this hypothetical case scenario even remotely possible by 2010 will require a concerted public health effort to translate genomic sequence data into new opportunities for disease prevention.

Traditionally, genetic diseases have been perceived as rare conditions resulting from high-penetrance mutations inherited in a Mendelian fashion such as Tay-Sachs disease.2 However, the etiology of common chronic diseases such as cancer, heart disease, and diabetes also has a significant genetic component. In these cases, inheritance is non-Mendelian and complex, making the causal genetic factors difficult to identify. Variants of multiple genes may each contribute a small part of the total risk for an individual. For example, evidence supports a role for common variants of a drug-metabolizing enzyme, N-acetyltransferase, in mediating susceptibility to sporadic bladder and colorectal cancer.3 Because these variants only become risk factors in the presence of bladder or colon carcinogens, they alter an individual's risk only slightly, but they may be responsible for a large number of cancers in populations that are exposed to carcinogens.3

Currently, because the presence of common genetic polymorphisms alone cannot accurately predict disease susceptibility, genetic tests for these variants rarely furnish information that can be used in prevention. The hope for the future is to learn what combination of gene variants and environmental factors predispose people to disease, and to use this information to prevent disease. For example, people who have the gene variant that codes for the "slow-acetylator" form of N-acetyltransferase, and who have a specific combination of other, as yet unidentified, risk factors, might be counseled to avoid working with bladder carcinogens like aniline dyes. In the future this model may provide targeted intervention and prevention. The US Centers for Disease Control and Prevention (CDC) has detailed the essential public health functions for genetics to play a role in disease prevention.4

Population based epidemiological studies are needed to learn the prevalence of gene variants that predispose people to disease, the burden of disease and death caused by these diseases, and the prevalence of disease-causing environmental exposures in genetically susceptible people. These studies are also needed to identify how environmental factors interact with genetic factors to cause disease. Such studies will often take years to complete, although in some cases, the information can be obtained retrospectively using incident case-control studies that are derived from population-based registries of diseases.5

For genetic tests to have practical value, they must be evaluated for their sensitivity, specificity, and positive predictive values in relation to measured genotypes (analytic validity) and specific health outcomes (clinical validity). To calculate these essential parameters, information about the prevalence and penetrance of disease-associated gene variants is required from population-based studies. When this information is available, genetic tests may improve the clinical predictive values of traditional risk factors for disease. For example, hypercholesterolemia is an independent risk factor for heart disease that can be treated with statin drugs.6 Because nearly one third of the US population has hypercholesterolemia, an important public health priority would be to optimize the cost-effectiveness of statin therapy. Genetic testing may one day identify the population that will benefit most from these drugs.

As more genetic tests are developed and marketed, it will be important to evaluate the value they add to existing medical and behavioral interventions. Population research will facilitate this evaluation of genetic testing and thereby prevent its misuse while helping to realize its benefits. Although new developments in genomic medicine will give physicians new tools for promoting health, preventing disease, and managing illness, they will also create a new responsibility to ensure they are used wisely and well.

Collins  FSPatrinos  AJordan  E  et al.  New goals for the US Human Genome Project:1998-2003. Science. 1998;2826829
Link to Article
Myerowitz  R Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat. 1997;9195- 208
Link to Article
Hein  DWDoll  MAFretland  AJ  et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;929- 42
Khoury  MJ Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev. 1997;19175- 180
Link to Article
Yang  QKhoury  MJCoughlin  SSSun  FFlanders  WD On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility. Genet Med. 2000;2186- 92
Link to Article
Jacobson  TA Clinical context: current concepts of coronary heart disease management. Am J Med. 2001;110 ((Suppl 6A)) 3S- 11S
Link to Article

Figures

Tables

References

Collins  FSPatrinos  AJordan  E  et al.  New goals for the US Human Genome Project:1998-2003. Science. 1998;2826829
Link to Article
Myerowitz  R Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat. 1997;9195- 208
Link to Article
Hein  DWDoll  MAFretland  AJ  et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;929- 42
Khoury  MJ Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev. 1997;19175- 180
Link to Article
Yang  QKhoury  MJCoughlin  SSSun  FFlanders  WD On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility. Genet Med. 2000;2186- 92
Link to Article
Jacobson  TA Clinical context: current concepts of coronary heart disease management. Am J Med. 2001;110 ((Suppl 6A)) 3S- 11S
Link to Article
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.